Summary:
- Sutro Biopharma, a clinical-stage drug discovery, development, and manufacturing company, presented data from the dose optimization portion of its REFINE-MFX study, which is evaluating STRO-002, an antibody-drug conjugate (ADC) for the treatment of advanced or recurrent ovarian cancer.
- The data showed that the dose optimization portion of the study successfully identified the recommended Phase 2 dose (RP2D) of STRO-002 at 5.2 mg/kg administered every 3 weeks, which demonstrated a favorable safety profile and promising anti-tumor activity.
- The company plans to advance STRO-002 into the expansion portion of the REFINE-MFX study to further evaluate the efficacy and safety of the RP2D in patients with advanced or recurrent ovarian cancer.